Lothar Krause
Research Subjects
Lothar Krause has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Michael H. Foerster
5 shared publicationsNikolaos E. Bechrakis
4 shared publicationsAndreas Altenburg
Dessau Medical Center
3 shared publications- Christos Constantin Zouboulis
Department of Dermatology, Venereology, and Immunology, Universitaetsklinikum Ruppin-Brandenburg, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Neuruppin, Germany
3 shared publications Anne-Katrin Köhler
Charité - Campus Benjamin Franklin
2 shared publications- Heinrich Heimann
Liverpool Ocular Oncology Centre, Liverpool University Hospitals Foundation Trust (LUHFT), Liverpool, United Kingdom; Liverpool Ocular Oncology Research Group, Department of Eye and Vision Science, Institute of Life Course and Medical Sciences (ILCaMS), University of Liverpool, Liverpool, United Kingdom
2 shared publications
Latest Publications
- 1 February 2009
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 44 (1) , 88-94
Incidence and outcome of endophthalmitis over a 13-year period
- 1 February 2009
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 44 (1) , 88-94
Incidence and outcome of endophthalmitis over a 13-year period
- 4 November 2008
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 247 (5) , 661-666
Ocular involvement in Adamantiades-Behçet’s disease in Berlin, Germany
Epidemiological studies demonstrate a prevalence of Adamantiades-Behçet’s disease (ABD) in the range of 0.12–420 per 100,000 inhabitants, with the highest rates in Istanbul, Turkey, and the lowest rates in the USA. Ophthalmological data on the prevalence of ocular involvement are limited for ABD in Germany, because most epidemiological studies are based on rheumatological or dermatological data. Berlin is the city with the highest number of non-native German inhabitants, and its multi-ethnic character renders it uniquely appropriate for epidemiological studies on ABD.
- 4 November 2008
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 247 (5) , 661-666
Ocular involvement in Adamantiades-Behçet’s disease in Berlin, Germany
Epidemiological studies demonstrate a prevalence of Adamantiades-Behçet’s disease (ABD) in the range of 0.12–420 per 100,000 inhabitants, with the highest rates in Istanbul, Turkey, and the lowest rates in the USA. Ophthalmological data on the prevalence of ocular involvement are limited for ABD in Germany, because most epidemiological studies are based on rheumatological or dermatological data. Berlin is the city with the highest number of non-native German inhabitants, and its multi-ethnic character renders it uniquely appropriate for epidemiological studies on ABD.
- 18 July 2008
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 225 (07) , 649-652
Rezidivhäufigkeit nach Exzision von Bindehautmelanomen und adjuvanter Strontium-90-Kontaktbestrahlung
Hintergrund: Aufgrund der hohen Rezidivrate nach Bindehautmelanomexzision wird eine adjuvante lokale Chemotherapie oder eine Bestrahlung empfohlen. Hierbei kommt u. a. die Strontium-90-Kontaktbestrahlung wegen der geringen Eindringtiefe der Strahlung infrage. Patienten und Methoden: 15 Patienten mit einem Bindehautmelanom erhielten nach Tumorexzision eine adjuvante Strontium-90-Kontaktbestrahlung. Diese erfolgte fraktioniert in neun Sitzungen à 6 Gy. Die durchschnittliche Nachbeobachtungszeit betrug 35 Monate (12 – 60 Monate). Ergebnisse: Bei 7 Patienten (46 %) zeigte sich im Beobachtungszeitraum kein Tumorrezidiv. Bei drei Patienten (20 %) kam es in den bestrahlten und benachbarten Arealen zu einem Rezidiv. Acht Patienten (53 %) wiesen neue Tumoren in nicht bestrahlten Bindehautarealen auf. Schlussfolgerungen: Durch eine adjuvante Strontium-90-Kontaktbestrahlung ist eine relativ sicher durchzuführende adjuvante Behandlung nach Exzision von Bindehautmelanomen. Häufige Nachkontrollen sind erforderlich, da sich weitere Tumoren in nicht bestrahlten Arealen ausbilden können, insbesondere beim Vorliegen einer Melanose. Background: Because of the high local recurrence rates after excision of conjunctival melanomas, adjuvant local chemotherapy or irradiation is recommended. Strontium-90 brachytherapy is one radiotherapeutic option due to its low penetration depth. Methods: 15 patients with conjunctival melanoma were treated with adjuvant strontium-90 brachytherapy after tumour excision. The treatment was fractionated into 9 irradiation sessions with 6 Gy each. The mean follow-up was 35 months (12 – 60 months). Results: Seven patients (46 %) had no recurrence during the follow-up. Three patients (20 %) had a recurrence in the treated or adjacent area. Eight patients (53 %) developed new tumours in non-treated areas. Conclusions: Strontium-90 brachytherapy is a useful adjuvant in the treatment of conjunctival melanomas. Regular ophthalmoscopic controls are necessary because of the high rate of new tumours in non-irradiated areas, especially in cases with primary acquired melanosis.
- 18 July 2008
- Published by Georg Thieme Verlag KG in Klinische Monatsblätter für Augenheilkunde
- Vol. 225 (07) , 649-652
Rezidivhäufigkeit nach Exzision von Bindehautmelanomen und adjuvanter Strontium-90-Kontaktbestrahlung
Hintergrund: Aufgrund der hohen Rezidivrate nach Bindehautmelanomexzision wird eine adjuvante lokale Chemotherapie oder eine Bestrahlung empfohlen. Hierbei kommt u. a. die Strontium-90-Kontaktbestrahlung wegen der geringen Eindringtiefe der Strahlung infrage. Patienten und Methoden: 15 Patienten mit einem Bindehautmelanom erhielten nach Tumorexzision eine adjuvante Strontium-90-Kontaktbestrahlung. Diese erfolgte fraktioniert in neun Sitzungen à 6 Gy. Die durchschnittliche Nachbeobachtungszeit betrug 35 Monate (12 – 60 Monate). Ergebnisse: Bei 7 Patienten (46 %) zeigte sich im Beobachtungszeitraum kein Tumorrezidiv. Bei drei Patienten (20 %) kam es in den bestrahlten und benachbarten Arealen zu einem Rezidiv. Acht Patienten (53 %) wiesen neue Tumoren in nicht bestrahlten Bindehautarealen auf. Schlussfolgerungen: Durch eine adjuvante Strontium-90-Kontaktbestrahlung ist eine relativ sicher durchzuführende adjuvante Behandlung nach Exzision von Bindehautmelanomen. Häufige Nachkontrollen sind erforderlich, da sich weitere Tumoren in nicht bestrahlten Arealen ausbilden können, insbesondere beim Vorliegen einer Melanose. Background: Because of the high local recurrence rates after excision of conjunctival melanomas, adjuvant local chemotherapy or irradiation is recommended. Strontium-90 brachytherapy is one radiotherapeutic option due to its low penetration depth. Methods: 15 patients with conjunctival melanoma were treated with adjuvant strontium-90 brachytherapy after tumour excision. The treatment was fractionated into 9 irradiation sessions with 6 Gy each. The mean follow-up was 35 months (12 – 60 months). Results: Seven patients (46 %) had no recurrence during the follow-up. Three patients (20 %) had a recurrence in the treated or adjacent area. Eight patients (53 %) developed new tumours in non-treated areas. Conclusions: Strontium-90 brachytherapy is a useful adjuvant in the treatment of conjunctival melanomas. Regular ophthalmoscopic controls are necessary because of the high rate of new tumours in non-irradiated areas, especially in cases with primary acquired melanosis.
- Open Access
- 13 June 2008
- Published by Springer Nature in Eye
- Vol. 23 (5) , 1182-1186
Ocular involvement is associated with HLA-B51 in Adamantiades–Behçet's disease
Purpose To evaluate the association of HLA-B51 and ocular involvement in Adamantiades–Behçet's disease. Methods We retrospectively analysed all patients with Adamantiades–Behçet's disease examined in our Department of Ophthalmology since 1982. All patients fulfilled the criteria of the International Study Group for Behçet's disease. We included 140 patients (63 female and 77 male) with a mean follow-up of 6.4 years. Results The mean age at the first manifestation was 23 years; full disease was noted at 32 years. The mean age at the time of eye involvement was 30 years. Most of the patients were of Turkish (n=73) or German (n=34) origin. A total of 56% patients developed eye involvement. Forty-nine out of 76 HLA-B51-positive patients (64.5%) and 26 out of 60 HLA-B51-negative patients (43.3%; P=0.014) developed ocular involvement. Conclusion More than the half of the patients with Adamantiades–Behçet's disease evaluated in our department developed ocular involvement. There was a statistically significantly higher frequency of HLA-B51 in these patients.
- 13 June 2008
- Published by Springer Nature in Eye
- Vol. 23 (5) , 1182-1186
Open AccessOcular involvement is associated with HLA-B51 in Adamantiades–Behçet's disease
Purpose To evaluate the association of HLA-B51 and ocular involvement in Adamantiades–Behçet's disease. Methods We retrospectively analysed all patients with Adamantiades–Behçet's disease examined in our Department of Ophthalmology since 1982. All patients fulfilled the criteria of the International Study Group for Behçet's disease. We included 140 patients (63 female and 77 male) with a mean follow-up of 6.4 years. Results The mean age at the first manifestation was 23 years; full disease was noted at 32 years. The mean age at the time of eye involvement was 30 years. Most of the patients were of Turkish (n=73) or German (n=34) origin. A total of 56% patients developed eye involvement. Forty-nine out of 76 HLA-B51-positive patients (64.5%) and 26 out of 60 HLA-B51-negative patients (43.3%; P=0.014) developed ocular involvement. Conclusion More than the half of the patients with Adamantiades–Behçet's disease evaluated in our department developed ocular involvement. There was a statistically significantly higher frequency of HLA-B51 in these patients.
- 15 April 2008
- Vol. 35 (5) , 896-903
Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
Relapsing ocular involvement is one of the major manifestations in Adamantiades-Behçet's disease (ABD). Combining systemic corticosteroids with cyclosporin A is currently the treatment of choice. Interferon-alpha (IFN-alpha) has proven to be effective in mucocutaneous ABD and has been reported to improve ocular lesions. We examined the longterm effects of IFN-alpha-2a in a case series of 45 patients with ocular involvement. Since 1988, 45 patients (79 eyes of 90 eyes) with ocular involvement in ABD have been treated with IFN-alpha (3 x 6-9 Mio IU per wk). In the initial acute phase of the disease, patients additionally received short-term corticosteroids (oral prednisolone 100 mg/day), tapered to a maintenance dose of 10 mg/day within 2 weeks. IFN-alpha-2a was administered as longterm therapy with a mean duration of 30 months (range 1.1-101 mo). IFN-alpha-2a/prednisolone treatment was effective against vasculitis, optic nerve neuropathy, and iritis. Sixty-four eyes had no recurrence under therapy. To date, recurrences have been seen in 26 eyes under IFN-alpha treatment. Flu-like symptoms were recorded in nearly all patients (n = 43). Further side effects were dose-dependent reversible thrombocytopenia (n = 1), psychosis (n = 3), depression (n = 13), thyroiditis (n = 1), and reversible diffuse alopecia (n = 7). In our series, 92% of all eyes showed stable or improved visual acuity in longterm followup. Longterm remission of ocular inflammation can be achieved with the combination of IFN-alpha and low-dose corticosteroids.
- 15 April 2008
- Vol. 35 (5) , 896-903
Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
Relapsing ocular involvement is one of the major manifestations in Adamantiades-Behçet's disease (ABD). Combining systemic corticosteroids with cyclosporin A is currently the treatment of choice. Interferon-alpha (IFN-alpha) has proven to be effective in mucocutaneous ABD and has been reported to improve ocular lesions. We examined the longterm effects of IFN-alpha-2a in a case series of 45 patients with ocular involvement. Since 1988, 45 patients (79 eyes of 90 eyes) with ocular involvement in ABD have been treated with IFN-alpha (3 x 6-9 Mio IU per wk). In the initial acute phase of the disease, patients additionally received short-term corticosteroids (oral prednisolone 100 mg/day), tapered to a maintenance dose of 10 mg/day within 2 weeks. IFN-alpha-2a was administered as longterm therapy with a mean duration of 30 months (range 1.1-101 mo). IFN-alpha-2a/prednisolone treatment was effective against vasculitis, optic nerve neuropathy, and iritis. Sixty-four eyes had no recurrence under therapy. To date, recurrences have been seen in 26 eyes under IFN-alpha treatment. Flu-like symptoms were recorded in nearly all patients (n = 43). Further side effects were dose-dependent reversible thrombocytopenia (n = 1), psychosis (n = 3), depression (n = 13), thyroiditis (n = 1), and reversible diffuse alopecia (n = 7). In our series, 92% of all eyes showed stable or improved visual acuity in longterm followup. Longterm remission of ocular inflammation can be achieved with the combination of IFN-alpha and low-dose corticosteroids.
- 10 April 2008
- Published by Springer Nature in International Ophthalmology
- Vol. 29 (4) , 207-212
Implantation of scleral fixated sutured posterior chamber lenses: a retrospective analysis of 119 cases
Background The implantation of scleral fixated sutured posterior chamber lenses enables lens implantation in the absence of adequate lens capsule support. Anterior chamber lenses and their side effects can also be avoided, particularly in cases of unilateral aphakia and contact lens incompatibility. Methods This study is a retrospective analysis of 119 scleral fixated sutured posterior chamber lenses implanted in 115 patients. Seventy-nine cases of damaged zonula or damaged lens capsule and 17 cases of corneal decompensation secondary to anterior chamber lenses were the main indications for the suture fixation. The mean follow-up was 23 months (6–83 months). Results In 50% of all cases, improved visual acuity was achieved. Twenty-four percent of patients showed unchanged visual acuity, while 26% had poorer vision postoperatively, mainly because of corneal decompensation following anterior chamber lens explantation. The main postoperative complication was transient rise of intraocular pressure, occurring in 44% of the cases. Conclusions In most cases improved or comparable postoperative visual acuity was achieved. The main complication observed was postoperative glaucoma, especially in patients with pre-existing glaucoma.
- 10 April 2008
- Published by Springer Nature in International Ophthalmology
- Vol. 29 (4) , 207-212
Implantation of scleral fixated sutured posterior chamber lenses: a retrospective analysis of 119 cases
Background The implantation of scleral fixated sutured posterior chamber lenses enables lens implantation in the absence of adequate lens capsule support. Anterior chamber lenses and their side effects can also be avoided, particularly in cases of unilateral aphakia and contact lens incompatibility. Methods This study is a retrospective analysis of 119 scleral fixated sutured posterior chamber lenses implanted in 115 patients. Seventy-nine cases of damaged zonula or damaged lens capsule and 17 cases of corneal decompensation secondary to anterior chamber lenses were the main indications for the suture fixation. The mean follow-up was 23 months (6–83 months). Results In 50% of all cases, improved visual acuity was achieved. Twenty-four percent of patients showed unchanged visual acuity, while 26% had poorer vision postoperatively, mainly because of corneal decompensation following anterior chamber lens explantation. The main postoperative complication was transient rise of intraocular pressure, occurring in 44% of the cases. Conclusions In most cases improved or comparable postoperative visual acuity was achieved. The main complication observed was postoperative glaucoma, especially in patients with pre-existing glaucoma.
- 13 April 2007
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 245 (11) , 1617-1621
Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease
Adamantiades-Behçet’s disease (ABD) is a multi-system disorder with recurrent oral and/or genital ulcerations, skin lesions and ocular involvement. Eye involvement is a common manifestation that affects the patients’ quality of life more than any other. Left untreated, it leads to blindness and often to loss of the eye through secondary complications like phthisis or painful glaucoma. In some cases, such as tractional retinal detachment, secondary glaucoma or secondary cataract formation, intraocular surgery is required.
- 13 April 2007
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 245 (11) , 1617-1621
Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet’s disease
Adamantiades-Behçet’s disease (ABD) is a multi-system disorder with recurrent oral and/or genital ulcerations, skin lesions and ocular involvement. Eye involvement is a common manifestation that affects the patients’ quality of life more than any other. Left untreated, it leads to blindness and often to loss of the eye through secondary complications like phthisis or painful glaucoma. In some cases, such as tractional retinal detachment, secondary glaucoma or secondary cataract formation, intraocular surgery is required.
- 1 April 2005
- Published by Springer Nature in Der Ophthalmologe
- Vol. 102 (4) , 329-334
Morbus Adamantiades-Beh et
Morbus Adamantiades-Behçet (MAB) ist eine chronische rezidivierende Systemvaskulitis, deren Ätiologie bis heute ungeklärt ist. Die Erstbeschreibung geht auf B. Adamantiades und H. Behçet zurück. Hauptsächlich tritt diese Erkrankung im Bereich des Mittelmeers, im mittleren und im fernen Osten auf. Die Erkrankung ist aber keinesfalls auf diese Länder beschränkt, sondern sie ist weltweit verbreitet und nimmt auch bei uns durch steigende Mobilität der Menschen stetig an Bedeutung zu. Klinisch finden sich rezidivierende orale und/oder genitale Aphthen, Arthritiden und eine Hautbeteiligung in Form von Erythema nodosum, Papulopusteln und eine superfizielle Thrombophlebitis. In bis zu 80% der Fälle tritt eine Beteiligung der Augen auf. Hierbei kommt es zu einer retinalen Vaskulitis, Optikusneuritis und häufig zu einer Uveitis. Die Augenbeteiligung kann in 20–50% der Fälle zu einer Erblindung der betroffenen Augen führen. In der Behandlung bei Augenbeteiligung stehen Steroide, Ciclosporin A und Azathioprin zur Verfügung. Neuere Medikamente wie Interferon-α oder TNF-Antikörper sind in Erprobung. Adamantiades-Behçet’s disease (ABD) is a chronic recurrent vasculitis whose aetiology is still unclear. The first description goes back to B. Adamantiades und H. Behçet. The disease mainly occurs in Mediterranean, Middle and Far Eastern countries. However, it is not limited to these regions and can be found worldwide, and, as a result of increasing human mobility, is steadily becoming more significant. Clinical findings reveal recurrent oral and/or genital ulcers, arthritis and skin involvement in the form of erythema nodosum and superficial thrombophlebitis. Relapsing ocular involvement is one of the major manifestations in ABD and can be found in 60–80% of patients, resulting in retinal vasculitis, neuropathy or panuveitis. Eye involvement can lead to blindness in the affected eye in 20–50% of cases. Steroids, cyclosporin A und azathioprin are available to treat affected eyes. Studies of new treatment modalities including interferon-α or TNF antibodies are under way.
- 1 April 2005
- Published by Springer Nature in Der Ophthalmologe
- Vol. 102 (4) , 329-334
Morbus Adamantiades-Beh et
Morbus Adamantiades-Behçet (MAB) ist eine chronische rezidivierende Systemvaskulitis, deren Ätiologie bis heute ungeklärt ist. Die Erstbeschreibung geht auf B. Adamantiades und H. Behçet zurück. Hauptsächlich tritt diese Erkrankung im Bereich des Mittelmeers, im mittleren und im fernen Osten auf. Die Erkrankung ist aber keinesfalls auf diese Länder beschränkt, sondern sie ist weltweit verbreitet und nimmt auch bei uns durch steigende Mobilität der Menschen stetig an Bedeutung zu. Klinisch finden sich rezidivierende orale und/oder genitale Aphthen, Arthritiden und eine Hautbeteiligung in Form von Erythema nodosum, Papulopusteln und eine superfizielle Thrombophlebitis. In bis zu 80% der Fälle tritt eine Beteiligung der Augen auf. Hierbei kommt es zu einer retinalen Vaskulitis, Optikusneuritis und häufig zu einer Uveitis. Die Augenbeteiligung kann in 20–50% der Fälle zu einer Erblindung der betroffenen Augen führen. In der Behandlung bei Augenbeteiligung stehen Steroide, Ciclosporin A und Azathioprin zur Verfügung. Neuere Medikamente wie Interferon-α oder TNF-Antikörper sind in Erprobung. Adamantiades-Behçet’s disease (ABD) is a chronic recurrent vasculitis whose aetiology is still unclear. The first description goes back to B. Adamantiades und H. Behçet. The disease mainly occurs in Mediterranean, Middle and Far Eastern countries. However, it is not limited to these regions and can be found worldwide, and, as a result of increasing human mobility, is steadily becoming more significant. Clinical findings reveal recurrent oral and/or genital ulcers, arthritis and skin involvement in the form of erythema nodosum and superficial thrombophlebitis. Relapsing ocular involvement is one of the major manifestations in ABD and can be found in 60–80% of patients, resulting in retinal vasculitis, neuropathy or panuveitis. Eye involvement can lead to blindness in the affected eye in 20–50% of cases. Steroids, cyclosporin A und azathioprin are available to treat affected eyes. Studies of new treatment modalities including interferon-α or TNF antibodies are under way.
- 17 December 2004
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 243 (6) , 545-550
Indocyanine green angiography and fluorescein angiography of malignant choroidal melanomas following proton beam irradiation
The vascularisation features of intraocular tumours may be characterised by indocyanine green angiography (ICG-A) and fluorescein angiography (FA). Proton beam irradiation is an established method of treating malignant melanoma of the choroid. The aim of this study was to describe the vascularisation features of small choroidal melanomas and to examine the influence of proton beam irradiation on these tumours. We examined 39 choroidal melanomas by ICG-A and FA from 1998 to 2001 in a prospective study. The tumours had a mean prominence of 3.65 mm (1.2–7.5 mm) and a common feature of all was their parapapillary or paramacular localisation. Angiography was always performed immediately before proton beam radiotherapy and at intervals of 3 months, half a year and 1 year thereafter. Two hundred and forty angiographies were analysed in total. Intra-tumoral vessels could be visualised in 89% of all tumours by ICG angiography but in only 33% by FA. Neither ICG-A nor FA detected changes 3 months after irradiation; however, ICG-A disclosed strong leakage from vessels in the tumour area after 6 months. These changes increased markedly after 12 months and were also visible by FA. A disadvantage of FA, however, was the faster escape of dye from the vessels, which caused rapid leakage in the tumour area and meant that details could no longer be demonstrated. ICG-A and FA detect marked vascular changes within the tumours examined.
- 17 December 2004
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 243 (6) , 545-550
Indocyanine green angiography and fluorescein angiography of malignant choroidal melanomas following proton beam irradiation
The vascularisation features of intraocular tumours may be characterised by indocyanine green angiography (ICG-A) and fluorescein angiography (FA). Proton beam irradiation is an established method of treating malignant melanoma of the choroid. The aim of this study was to describe the vascularisation features of small choroidal melanomas and to examine the influence of proton beam irradiation on these tumours. We examined 39 choroidal melanomas by ICG-A and FA from 1998 to 2001 in a prospective study. The tumours had a mean prominence of 3.65 mm (1.2–7.5 mm) and a common feature of all was their parapapillary or paramacular localisation. Angiography was always performed immediately before proton beam radiotherapy and at intervals of 3 months, half a year and 1 year thereafter. Two hundred and forty angiographies were analysed in total. Intra-tumoral vessels could be visualised in 89% of all tumours by ICG angiography but in only 33% by FA. Neither ICG-A nor FA detected changes 3 months after irradiation; however, ICG-A disclosed strong leakage from vessels in the tumour area after 6 months. These changes increased markedly after 12 months and were also visible by FA. A disadvantage of FA, however, was the faster escape of dye from the vessels, which caused rapid leakage in the tumour area and meant that details could no longer be demonstrated. ICG-A and FA detect marked vascular changes within the tumours examined.